{"title":"慢性疲劳综合征和纤维肌痛(CFS/FMS)的营养干预——一种独特的猪血清多肽营养补充剂","authors":"J. Teitelbaum, Gaetano Morello, Sarah Goudie","doi":"10.2174/1876386302013010052","DOIUrl":null,"url":null,"abstract":"\n \n Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases.\n \n \n \n The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS).\n \n \n \n An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide.\n \n \n \n Four 500 mg tablets twice daily for five weeks.\n \n\n \n \n Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms.\n \n \n \n 43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better.\n In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories:\n 1. 69.4% increase in energy(p<.001)\n 2. 69.2% increase in overall well-being(<.001)\n 3. 53.8% improvement in sleep(<.001)\n 4. 60.5% improvement in mental clarity(<.001)\n 5. 37.9% decrease in pain(<.013)\n 6. 34.8% decrease in anxiety(<.001)\n 7. 54.6% improvement in digestive symptoms(<.001)\n 8. FIQR 59.2 to 39.3(<.001)\n In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets.\n\n \n \n \n Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS.\n \n \n \n Clinical Trial Registration Number: NCT04381793.\n","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nutritional Intervention in Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) A Unique Porcine Serum Polypeptide Nutritional Supplement\",\"authors\":\"J. Teitelbaum, Gaetano Morello, Sarah Goudie\",\"doi\":\"10.2174/1876386302013010052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases.\\n \\n \\n \\n The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS).\\n \\n \\n \\n An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide.\\n \\n \\n \\n Four 500 mg tablets twice daily for five weeks.\\n \\n\\n \\n \\n Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms.\\n \\n \\n \\n 43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better.\\n In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories:\\n 1. 69.4% increase in energy(p<.001)\\n 2. 69.2% increase in overall well-being(<.001)\\n 3. 53.8% improvement in sleep(<.001)\\n 4. 60.5% improvement in mental clarity(<.001)\\n 5. 37.9% decrease in pain(<.013)\\n 6. 34.8% decrease in anxiety(<.001)\\n 7. 54.6% improvement in digestive symptoms(<.001)\\n 8. FIQR 59.2 to 39.3(<.001)\\n In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets.\\n\\n \\n \\n \\n Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS.\\n \\n \\n \\n Clinical Trial Registration Number: NCT04381793.\\n\",\"PeriodicalId\":53614,\"journal\":{\"name\":\"Open Pain Journal\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Pain Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876386302013010052\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Pain Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876386302013010052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Nutritional Intervention in Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) A Unique Porcine Serum Polypeptide Nutritional Supplement
Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases.
The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS).
An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide.
Four 500 mg tablets twice daily for five weeks.
Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms.
43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better.
In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories:
1. 69.4% increase in energy(p<.001)
2. 69.2% increase in overall well-being(<.001)
3. 53.8% improvement in sleep(<.001)
4. 60.5% improvement in mental clarity(<.001)
5. 37.9% decrease in pain(<.013)
6. 34.8% decrease in anxiety(<.001)
7. 54.6% improvement in digestive symptoms(<.001)
8. FIQR 59.2 to 39.3(<.001)
In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets.
Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS.
Clinical Trial Registration Number: NCT04381793.